tiprankstipranks
Cue Biopharma sees cash, securities funding operations through Q3 of 2024
The Fly

Cue Biopharma sees cash, securities funding operations through Q3 of 2024

As of June 30, the company had approximately $57.9M in cash, cash equivalents and marketable securities compared with $66.1M as of June 30, 2022. The company expects its current cash, cash equivalents, and marketable securities to fund operations through Q3 of 2024.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on CUE:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles